Home › Funds › Longaeva Partners L.P. › RYTM

Longaeva Partners L.P. position in RYTM

RHYTHM PHARMACEUTICALS INC · Health Care

Longaeva Partners L.P. reported holding 516,418 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$49.2M, representing 1.24% of its reported portfolio and ranking #9 among its reported holdings. Longaeva Partners L.P. has disclosed RYTM holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)516.42K sh
Reported value held$49.17M
Portfolio Weight1.24%
First reportedQ2 2026
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Longaeva Partners L.P.'s RYTM position evolved

Longaeva Partners L.P. first disclosed a stake in RYTM in Q2 2026 at 110,074 shares (US$12.2M). The position peaked in Q3 2026 at 516,418 shares, worth US$49.2M. Across 2 filings, Longaeva Partners L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 516,418 shares valued at US$49.2M — an increase of 406,344 shares quarter over quarter.. Notable position changes include a 369% increase in Q3 2026 (shares rose 13% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2026 110.07K $12.22M New
Q3 2026 516.42K $49.17M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RYTM and 13F data

RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 41 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$634.8M), BAKER BROS. ADVISORS LP (US$533.6M), PERCEPTIVE ADVISORS LLC (US$241.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RYTM

All RYTM fund holders →

FAQ

How long has Longaeva Partners L.P. held RYTM?

Longaeva Partners L.P. has disclosed RYTM holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Longaeva Partners L.P.'s current position in RYTM?

As of Q3 2026, Longaeva Partners L.P. holds 516.42K shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $49.17M, representing 1.24% of its reported portfolio and ranking #9.

Has Longaeva Partners L.P. been buying or selling RYTM?

In the latest 13F filing (Q3 2026), Longaeva Partners L.P. increased its position in RYTM. The position peaked in Q3 2026 at 516.42K shares.

Which other funds hold RYTM?

Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.